Loading...
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
Meirson, Tomer Nardone, Valerio Pentimalli, Francesca Markel, Gal Bomze, David D'Apolito, Maria Correale, Pierpaolo Pirtoli, Luigi Porta, Camillo
Meirson, Tomer
Nardone, Valerio
Pentimalli, Francesca
Markel, Gal
Bomze, David
D'Apolito, Maria
Correale, Pierpaolo
Pirtoli, Luigi
Porta, Camillo
Citations
Altmetric:
Genre
Journal article
Date
2022-12-13
Advisor
Committee member
Department
Biology
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.1186/s12967-022-03744-6
Abstract
In this commentary, using existing clinical trial data and FDA approvals we propose that there is currently a critical need for an appropriate balancing between the financial impact of new cancer drugs and their actual benefit for patients. By adopting “pleural mesothelioma” as our clinical model we summarize the most relevant pertinent and available literature on this topic, and use an analysis of the reliability of the trials submitted for registration and/or recently published as a case in point to raise concerns with respect to appropriate trial design, biomarker based stratification and to highlight the ongoing need for balancing the benefit/cost ratio for both patients and healthcare providers.
Description
Citation
Meirson, T., Nardone, V., Pentimalli, F. et al. Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology. J Transl Med 20, 593 (2022). https://doi.org/10.1186/s12967-022-03744-6
Citation to related work
BMC
Has part
Journal of Translational Medicine, Vol. 20
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu